두개내 동맥류 : 시장 점유율 분석, 업계 동향과 통계, 성장 예측(2026-2031년)

According to Mordor Intelligence, the intracranial aneurysm market size is expected to grow from USD 2.51 billion in 2025 to USD 2.76 billion in 2026 and is forecast to reach USD 4.44 billion by 2031 at 9.98% CAGR over 2026-2031.

This report is Segmented by Treatment Type (Endovascular Coiling, and More), Diagnosis (Computed Tomography Angiography, and More), End-User (Hospitals, Ambulatory Surgical Centers, Specialty Neurosurgical Centers), and Geography (North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa). Market Forecasts are Provided in Terms of Value (USD).

Global Intracranial Aneurysm Market Trends and Insights

Rising Demand for Minimally Invasive Endovascular Procedures

Endovascular coiling has moved from a focus on ruptured lesions to broad use in unruptured aneurysms, setting lower treatment thresholds and favoring earlier intervention as centers optimize catheter-based workflows. Patients see shorter hospital stays and faster returns to normal activity compared with open surgery because craniotomy is avoided and perioperative risk is reduced. Flow diverters extend minimally invasive logic to complex and large aneurysms by redirecting blood flow across the neck and encouraging sac thrombosis, which streamlines device counts and reduces need for adjunctive stents. U.S. regulatory programs that prioritize devices addressing life-threatening conditions support faster review of next-generation flow-diverter and intrasaccular systems, which accelerates the cadence of therapeutic innovation. Increased procedural volumes motivate hospitals and specialized centers to invest in biplane angiography suites and higher resolution imaging, which in turn expands treatable anatomy and broadens the candidate pool among patients previously deemed unsuitable. Credentialing and training requirements shape adoption curves, but the cumulative direction of travel favors catheter-based modalities in both elective and acute settings.

Growing Detection of Unruptured IA Through Incidental Brain Imaging

Routine CT and MRI use for non-specific neurologic symptoms and trauma is identifying aneurysms in 2-3% of asymptomatic individuals as scanner resolution and utilization rise. The increase in incidental findings pushes more triage decisions into specialty clinics, where physicians weigh the low annual rupture risk of small aneurysms against patient anxiety and medico-legal considerations. High-income health systems with abundant imaging capacity register the highest detection rates, with Japan's scanning intensity serving as a benchmark among OECD countries. Centralized stroke networks help absorb referral surges by consolidating neuro-intervention expertise in accredited centers that maintain round-the-clock access to endovascular care. AI algorithms now embedded in radiology workflows flag candidate lesions for review, which lifts sensitivity but can also lengthen worklists and channel more patients into surveillance or treatment pathways. The combined effect is a sustained pipeline of unruptured aneurysm referrals that strengthens the procedure base for the intracranial aneurysm market.

Shortage of Dual-Trained Endovascular Neurosurgeons in Emerging Markets

Endovascular aneurysm care requires combined skill sets in neurosurgery and interventional techniques that take years to develop. Training pipelines in developed regions supply enough operators to sustain volumes, but emerging geographies train far fewer specialists than current prevalence and detection would suggest. This mismatch creates geographic access gaps outside major cities and leads to patient travel or delayed treatment for elective cases. Building comprehensive stroke centers involves investments in angiography, neuro-ICU, and on-call neurosurgery, which slows ramp-up in resource-constrained environments. Policy initiatives that tie reimbursement to stroke center accreditation and outcomes have improved coverage in select countries, yet workforce scale remains a binding constraint. Tele-proctoring pilots indicate avenues for skill transfer and scale, but liability and credentialing ambiguity still limit reach.

Other drivers and restraints analyzed in the detailed report include:

1. Aging-Linked Hypertension and Smoking Prevalence in Developing Economies
2. Regulatory Fast-Tracks Compressing Approval Timelines
3. High Device and Procedural Costs With Uneven Reimbursement Coverage

For complete list of drivers and restraints, kindly check the Table Of Contents.

Segment Analysis

Endovascular coiling held a 22.36% share in 2025, and its durability across rupture status and aneurysm sizes keeps it foundational, while single-device architectures are rising for wide-necked lesions. Flow diverters are the fastest-growing category at a 12.34% CAGR to 2031 as operators reduce adjunctive stenting and coil counts for large and fusiform anatomies that previously demanded multi-device stacks. Intrasaccular flow disruptors attract use at bifurcations where coil retention is challenging and parent-vessel protection is essential. Adjunctive balloon- and stent-assisted coiling still contribute in anatomies where vessel geometry or neck configuration requires additional stabilization. Microsurgical clipping is increasingly reserved for younger patients with select bifurcations or cases where mass effect compels decompression, which sustains a smaller but essential surgical niche. Credentialing and training requirements have tightened after delayed ischemic events were observed in post-market registries for certain implants, prompting additional proctoring and center-level reviews to standardize use.

Device profile miniaturization now enables distal navigation through 0.017-inch microcatheters for newer flow diverters, extending reach beyond first-generation systems and increasing the proportion of treatable cases. Surface-engineered implants aim to cut the duration of dual antiplatelet therapy, and early clinical experience suggests faster endothelialization without compromising deliverability. For operators and centers, fewer devices per case and shorter procedure times improve resource utilization and throughput. As regulatory oversight emphasizes traceability and quality, device makers align with ISO 13485 and MDR standards to maintain compliant production and surveillance systems. The intracranial aneurysm market benefits from these engineering and process improvements because complex cases can be treated in a broader set of facilities with predictable protocols. The intracranial aneurysm market size for flow diverters is projected to expand at 12.34% CAGR between 2026-2031, reinforcing their role in reshaping therapy mix.

Complete Report Scope:

• By Treatment Type
  • Endovascular Coiling
  • Stent-Assisted Coiling
  • Balloon-Assisted Coiling
  • Flow Diverter Stents
  • Intrasaccular Flow Disruptors (e.g., WEB, Contour)
  • Microsurgical Clipping
• By Diagnosis
  • Computed Tomography Angiography (CTA)
  • Magnetic Resonance Angiography (MRA)
  • Digital Subtraction Angiography (DSA; incl. biplane, 3DRA)
  • 3D Rotational Angiography / 4D CTA
  • High-Resolution Vessel Wall MRI
• By End-user
  • Hospitals
  • Ambulatory Surgical Centers
  • Specialty Neurosurgical Centers

Geography Analysis

North America represented 43.14% of revenue in 2025, with growth normalizing to the 7-8% range as detection and treatment penetration reach mature levels. The region's structure relies on a large base of accredited comprehensive stroke centers that maintain 24/7 neuro-interventional capabilities and robust quality management. Canada centralizes neuro-intervention in provincial hubs, which sustains expertise while increasing wait times for non-urgent cases compared with private U.S. centers. Innovation cycles in microcatheters, surface-engineered flow diverters, and imaging software differentiate vendors and shape purchasing committees in a market where reimbursement already supports advanced devices. Payers rely on DRG frameworks and negotiated rates that reward efficiency and low complications, so centers focus on reducing fluoroscopy exposure, shortening time to hemostasis, and optimizing discharge. The intracranial aneurysm market remains competitive in North America as vendors seek clinical and economic advantages that sway hospital value analysis committees.

Europe shows country-level variability around similar clinical care standards, with reimbursement and assessment bodies determining access to advanced implants such as flow diverters. Social insurance systems in markets like Germany often bundle device costs in case rates, while centralized HTA processes in others constrain indications or restrict coverage to larger aneurysms. Strong registry cultures in parts of Europe generate comparative outcomes evidence that influences practice and supports protocol standardization. Under the MDR framework, device makers maintain traceable quality systems and generate more extensive clinical evidence in post-market surveillance, which favors firms with established regulatory infrastructure. Academic centers across the region enroll heavily in pivotal neurovascular device trials, improving speed of evidence generation for new indications. The intracranial aneurysm market in Europe remains stable and evidence-led, with adoption gated by value assessments and clinical data production cycles.

Asia-Pacific is the fastest-growing region at an 11.19% CAGR through 2031 as governments and private systems expand imaging access and designate stroke centers in more cities. China's policies prioritize stroke-center expansion and interventional training, contributing to higher volumes in tier-two urban markets and gradual diffusion into surrounding regions. Japan's established interventional ecosystem achieves high treatment rates, and its regulatory system maintains rigorous local review processes that can delay imported devices while creating room for domestic players. India's payer mix and uneven facility distribution create a two-speed pattern, with metropolitan private hospitals adopting the latest neurovascular devices while many secondary cities still lack angiography suites. Southeast Asian countries expand capacity with external training partnerships and medical tourism programs that attract patients from less developed neighbors. Regional regulatory frameworks range from Singapore's close alignment with U.S. standards to China's acceleration of domestic approvals, shaping the sequence and breadth of device introductions in the intracranial aneurysm market.

1. Acandis
2. ASAHI INTECC
3. B. Braun (Aesculap)
4. Balt
5. Cerus Endovascular
6. Evasc Neurovascular
7. GE HealthCare (angiography/CT)
8. Integra LifeSciences (Codman Specialty Surgical)
9. Johnson & Johnson (CERENOVUS)
10. Kaneka
11. Medtronic
12. MicroPort
13. Penumbra
14. Perflow Medical
15. Philips (angiography/CT/MR)
16. Rapid Medical
17. Route 92 Medical
18. Siemens Healthineers (angiography/CT/MR)
19. Stryker
20. Terumo (MicroVention)
21. United Imaging (CT/MR/angiography)
22. Wallaby Medical

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support

TABLE OF CONTENTS

1 Introduction

• 1.1 Study Assumptions & Market Definition
• 1.2 Scope of the Study

2 Research Methodology

3 Executive Summary

4 Market Landscape

• 4.1 Market Overview
• 4.2 Market Drivers
  • 4.2.1 Rising Demand for Minimally Invasive Endovascular Procedures
  • 4.2.2 Growing Detection of Unruptured IA Through Incidental Brain Imaging
  • 4.2.3 Aging-Linked Hypertension and Smoking Prevalence in Developing Economies
  • 4.2.4 Regulatory Fast-Tracks Compressing Approval Timelines
  • 4.2.5 Emergence of AI-Guided Robotic Neuro-Intervention Platforms
  • 4.2.6 Venture Funding into Nano-Engineered Coil/Implant Surface Technologies
• 4.3 Market Restraints
  • 4.3.1 High Device and Procedural Costs with Uneven Reimbursement Coverage
  • 4.3.2 Shortage of Dual-Trained Endovascular Neurosurgeons in Emerging Markets
  • 4.3.3 Device-Related Thrombo-Embolic Risks and DAPT Adherence Challenges
  • 4.3.4 Exposure to Platinum/Cobalt Price Volatility Across the Supply Chain
• 4.4 Value / Supply-Chain Analysis
• 4.5 Regulatory Landscape
• 4.6 Technological Outlook
• 4.7 Porter's Five Forces
  • 4.7.1 Threat of New Entrants
  • 4.7.2 Bargaining Power of Buyers/Consumers
  • 4.7.3 Bargaining Power of Suppliers
  • 4.7.4 Threat of Substitute Products
  • 4.7.5 Intensity of Competitive Rivalry

5 Market Size & Growth Forecasts (Value, in USD)

• 5.1 By Treatment Type
  • 5.1.1 Endovascular Coiling
  • 5.1.2 Stent-Assisted Coiling
  • 5.1.3 Balloon-Assisted Coiling
  • 5.1.4 Flow Diverter Stents
  • 5.1.5 Intrasaccular Flow Disruptors (e.g., WEB, Contour)
  • 5.1.6 Microsurgical Clipping
• 5.2 By Diagnosis
  • 5.2.1 Computed Tomography Angiography (CTA)
  • 5.2.2 Magnetic Resonance Angiography (MRA)
  • 5.2.3 Digital Subtraction Angiography (DSA; incl. biplane, 3DRA)
  • 5.2.4 3D Rotational Angiography / 4D CTA
  • 5.2.5 High-Resolution Vessel Wall MRI
• 5.3 By End-user
  • 5.3.1 Hospitals
  • 5.3.2 Ambulatory Surgical Centers
  • 5.3.3 Specialty Neurosurgical Centers

6 Competitive Landscape

• 6.1 Market Concentration
• 6.2 Market Share Analysis
• 6.3 Company Profiles (includes Global level Overview, Market level overview, Core Segments, Financials as available, Strategic Information, Market Rank/Share for key companies, Products & Services, and Recent Developments)
  • 6.3.1 Acandis GmbH
  • 6.3.2 ASAHI INTECC
  • 6.3.3 B. Braun (Aesculap)
  • 6.3.4 Balt
  • 6.3.5 Cerus Endovascular
  • 6.3.6 Evasc Neurovascular
  • 6.3.7 GE HealthCare (angiography/CT)
  • 6.3.8 Integra LifeSciences (Codman Specialty Surgical)
  • 6.3.9 Johnson & Johnson (CERENOVUS)
  • 6.3.10 Kaneka Corporation
  • 6.3.11 Medtronic
  • 6.3.12 MicroPort Scientific
  • 6.3.13 Penumbra Inc.
  • 6.3.14 Perflow Medical
  • 6.3.15 Philips (angiography/CT/MR)
  • 6.3.16 Rapid Medical
  • 6.3.17 Route 92 Medical
  • 6.3.18 Siemens Healthineers (angiography/CT/MR)
  • 6.3.19 Stryker
  • 6.3.20 Terumo (MicroVention)
  • 6.3.21 United Imaging (CT/MR/angiography)
  • 6.3.22 Wallaby Medical

7 Market Opportunities & Future Outlook

• 7.1 White-space & Unmet-need Assessment